References
- Comenzo R L, Vosburgh E, Simms R W, Bergethon P, Sarnecki D, Finn K, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88: 2801–2806
- Dispenzieri A, Kyle R A, Lacy M Q, Therneau T M, Larson D R, Plevak M F, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem transplantation: a case-control study. Blood 2004; 103: 3960–3963
- Skinner J, Sanchorawala V, Seldin D C, Dember L M, Falk R H, Berk J L, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93
- Gertz M A, Comenzo R, Falk R H, Fermand J P, Hazenberg B P, Hawkins P N, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion form the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005; 79: 319–328
- Leung N, Leung T R, Cha S C, Dispenzieri A, Lacy M Q, Gertz M A. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005; 106: 3353–3357
- Sanchorawala V, Wright D G, Seldin D C, Falk R H, Finn K T, Dember L M, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381–388
- Gertz M A, Kyle R A, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and waldenstrom's macroglobulinemia. J Clin Oncol 1993; 11: 914–920
- Ikee R, Kobayashi S, Hemmi N. Amyloidosis associated with chronic lymphocytic leukemia. Amyloid 2005; 12: 131–134
- Wechalekar A D, Goodman H J, Gilmore J D, Lachmann H J, Offer M, Bradwell A R, Hawkins P N. Clinical profile and treatment outcome in 92 patients with AL amyloidosis associated with IgM paraproteinaemia. Blood 2005; 106: 977, α(abstract 3498)
- Valente M, Roy V, Lacy M Q, Dispenzieri A, Gertz M A. Autologous stem cell transplantation and IgM amyloidosis. Leuk Lymphoma 2006; 47: 1006–1012
- Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermme O, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: Results of the French Multicentric Randomized Trial (MAG and IFM InterGroup). Blood 2005; 106: 127, α(abstract 421)